borderline significantp = 0.046
In contrast, there was no difference in distant cancer recurrence between patients with or without CTA-expression in TFL in the discovery cohort, while in the validation cohort the difference in distant cancer recurrence between patients with and without CTA-expression in TFL was small and borderline significant ( p = 0.046) ( Figure S6 ).